CO14. A pivotal study evaluating efficacy and safety of the hedgehog pathway inhibitor (HPI) vismodegib (GDC-0449) in patients with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC)

A Sekulic,J.A Solomon,A.L.S Chang,M.R Migden,J.D Hainsworth,J.C Reddy,S.T Arron,C.M Rudin,S Yoo,A.E Oro,J.A Low,E Marmur,A.B Mueller,A Hauschild,R.L Yauch,K Lewis,P.A Friedlander,L Dirix

doi:10.1097/01.cmr.0000399448.65869.b7

CO14. A pivotal study evaluating efficacy and safety of the hedgehog pathway inhibitor (HPI) vismodegib (GDC-0449) in patients with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC)

A Sekulic, J.A Solomon + Show 16 more

https://doi.org/10.1097/01.cmr.0000399448.65869.b7

Copy DOI

Journal: Melanoma Research	Publication Date: Jun 1, 2011
Citations: 9

Affiliation: Northwestern University, Mount Sinai Medical Center, University Hospital Schleswig-Holstein, University of Lübeck, University of Colorado Denver, University of Colorado Cancer Center, GZA Ziekenhuizen Campus Sint-Augustinus

#Hedgehog Pathway Inhibitor #Hedgehog Pathway Inhibitor Vismodegib + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

CO14. A pivotal study evaluating efficacy and safety of the hedgehog pathway inhibitor (HPI) vismodegib (GDC-0449) in patients with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC)

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Melanoma Research

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.